Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort

INTRODUCTION: Atopic dermatitis (AD) is a highly prevalent, chronic, inflammatory skin disease. Several orally administered Janus kinase inhibitors (JAKis, including baricitinib, upadacitinib and abrocitinib) have received a marketing authorisation for AD. Clinical trials in rheumatoid arthritis (RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Berthe, Pauline, Scailteux, Lucie-Marie, Lescoat, Alain, Staumont, Delphine, Coiffier, Guillaume, Guéret, Pierre, Dupuy, Alain, Oger, Emmanuel, Droitcourt, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494565/
https://www.ncbi.nlm.nih.gov/pubmed/36130766
http://dx.doi.org/10.1136/bmjopen-2021-059979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494565/
https://www.ncbi.nlm.nih.gov/pubmed/36130766
http://dx.doi.org/10.1136/bmjopen-2021-059979

Ejemplares similares